Why does the randomized clinical trial methodology so often mislead clinical decision making?focus on moderators and mediators of treatment

Psychiatric Annals

Volumn 39, Issue 7, 2009, Pages 736-745

  Kraemer, Helena Chmura ^a   Gibbons, Robert D ^b  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77649103297     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/00485713-20090625-06     Document Type: Article

References (39)

1. Rennie D. How to report randomized controlled trials: the CONSORT statement. JAMA. 1996;276(8):649.
2. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA. 1999;276(8):637-639.
3. Altman DG, Schulz KF, Hoher D, et al; CONSORT Group. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134(8):663-694.
4. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ. Reporting of Noninferiority and Equivalence Randomized Trials: an extension of the CONSORT Statement. JAMA. 2006;295(10):1152-1160.
5. Kline RB. Beyond Significance Testing: Reforming Data Analysis Methods in Behavioral Research. Washington, DC: American Psychological Association; 2005.
6. Nickerson RS. Null hypothesis significance testing: a review of an old and continuing controversy. Psychol Methods. 2000;5(2):241-301.
7. Wilkinson L. The Task Force on Statistical Inference. Statistical Methods in Psychology Journals: Guidelines and Explanations. American Psychologist. 1999;54:594-604.
8. Thompson B. Journal editorial policies regarding statistical significance tests: heat is to fire as P is to importance. Educational Psychology Review. 1999;11:157-169.
9. Krantz DH. The null hypothesis testing controversy in psychology. Journal of the American Statistical Association. 1999;44(448):1372-1381.
10. Shrout PE. Should significance tests be banned? Introduction to a special section exploring the pros and cons. Psychological Science. 1997;8(1):1-2.
11. Hunter JE. Needed: a ban on the significance test. Psychological Science. 1997;8(1):3-7.
12. Hsu LM. Biases of success rate differences shown in binomial effect size displays. Psychol Methods. 2004;9(2):183-197.
13. Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry. 2006;59(11):990-996.
14. Jones LV, Tukey JW. A sensible formulation of the significance test. Psychol Methods. 2000;5(4):411-414.
15. Meehl PE. Theory testing in psychology and physics: a methodological paradox. Philosophy of Science. 1967;34:103-115.
16. Meehl PE. Theoretical risks and tabular asterisks: Sir Karl, Sir Ronald, and the slow progress of soft psychology. Journal of Consulting and Clinical Psychology. 1978;46:806-834.
17. Wen L, Badgett R, Cornell J. Number needed to treat: A descriptor for weighing therapeutic options. Am J Health Sys Pharm. 2005;62(19):2031-2036.
18. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310(6977):452-454.
19. Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998;317(7168):1309-1312.
20. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
21. Miller FG. Placebo-controlled trials in psychiatric research: an ethical perspective. Biol Psychiatry. 2000;47(8):707-716.
22. Lavori PW. Placebo control groups in randomized treatment trials: a statistician's perspective. Biol Psychiatry. 2000;47(8):717-723.
23. Hill AB. Medical ethics and controlled trials. BMJ. 1963;1(5337):1043-1049.
24. Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med. 1994;331(6):394-398.
25. Humphreys K, Weingardt KR, Horst D, Joshi AA, Finney JW. Prevalence and predictors of research participant eligibility criteria in alcohol treatment outcome studies, 1970-98. Society for the Study of Addiction. 2005;100:1249-1257.
26. Hoagwood K, Hibbs E, Brent D, Jensen P. Introduction to the Special Section: Efficacy and Effectiveness in Studies of Child and Adolescent Psychotherapy. J Consult Clin Psychol. 1995;63(5):683-687.
27. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317(3)141-145.
28. Baron RM, Kenny DA. The Moderator-Mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986;51(6):1173-1182.
29. Kraemer HC, Stice E, Kazdin A, Kupfer D. How do risk factors work together to produce an outcome? Mediators, moderators, independent, overlapping and proxy risk factors. Am J Psychiatry. 2001;158(6):848-856.
30. Kraemer HC, Wilson GT, Fairburn CG, Agras WS. Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry. 2002;59(10):877-883.
31. Kraemer HC, Frank E, Kupfer DJ. Moderators of treatment outcomes: clinical, research, and policy importance. JAMA. 2006;296(10):1-4.
32. Kraemer HC, Kiernan M, Essex MJ, Kupfer DJ. How and why criteria defining moderators and mediators differ between the Baron & Kenny and MacArthur approaches. Health Psychology. 2008;27(2):S101-S108.
33. Kraemer HC. Toward non-parametric and clinically meaningful moderators and mediators. Stat Med. 2008;27(10):1679-1692.
34. Murphy GM, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonic transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry. 2004;61(11):1163-1169.
35. The MTA Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of Children with Attention-deficit/hyperactivity Disorder. Arch Gen Psychiatry. 1999;56(12):1088-1096.
36. Kraemer HC, Blasey C. Centering in regression analysis: a strategy to prevent errors in statistical inference. Int J Methods Psychiatr Res. 2004;13(3):141-151.
37. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder: Modal Treatment Study of Children with Attention-deficit/hyperactivity Disorder. Arch Gen Psychiatry. 1999;56(12):1073-1086.
38. Infant Health and Development Program. Enhancing the outcomes of low birth weight, premature infants: a multisite randomized trial. JAMA. 1990;263(22):3035-3042.
39. Kraemer HC. Pitfalls of multisite randomized clinical trials of efficacy and effectiveness. Schizophr Bull. 2000;26(3):535-543.